Pseudoprogression and immune-related response in solid tumors

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3541-3543

  Chiou, Victoria L ^a   Burotto, Mauricio ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; ATEZOLIZUMAB; CD274 PROTEIN, HUMAN; LIGAND; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER STAGING; HUMAN; IMMUNE RESPONSE; MELANOMA; METASTATIC MELANOMA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; GENE EXPRESSION REGULATION; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; NEOPLASMS; PROCEDURES; SKIN NEOPLASMS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; LIGANDS; LUNG NEOPLASMS; MELANOMA; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84947248057     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.61.6870     Document Type: Note

References (22)

1. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570, 2011
2. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
3. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
4. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
5. Fojo AT, Noonan A: Why RECIST works and why it should stay: Counterpoint. Cancer Res 72:5151-5157, 2012
6. Di Giacomo AM, Danielli R, Guidoboni M, et al: Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: Clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297-1306, 2009
7. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
8. Hodi FS, Sznol M, Kluger HM, et al: Long term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol 32, 2014 (suppl 15s; abstr 9002)
9. Hodi FS, Ribas A, Daud A, et al: Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol 32, 2014 (suppl 15s; abstr 3006)
10. Wolchok JD, Kluger H, Callahan MK, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-133, 2013
11. Weber JS, Kudchadkar RR, Yu B, et al: Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 31:4311-4318, 2013
12. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
13. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
14. Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 384:1109-1117, 2014
15. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558-562, 2014
16. Motzer RJ, Rini BI, McDermott DF, et al: Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33:1430-1437, 2015
17. Herbst RS, Soria JC, Kowanetz M, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-567, 2014
18. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-144, 2013
19. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
20. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
21. Rizvi NA, Mazières J, Planchard D, et al: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 16:257-265, 2015
22. Weber JS, D'Angelo SP, Minor D, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375-384, 2015